November 2, 2020 -- PerkinElmer has reached an agreement to acquire Horizon Discovery Group with an all-cash offer of approximately $383 million. The transaction is expected to close in the first quarter of 2021.
With this acquisition, PerkinElmer will expand its portfolio of automated life sciences discovery and applied genomics technologies including gene editing and gene modulation tools. This will complement PerkinElmer's existing products including immunoassay platforms, high-content screening and in vivo imaging, microfluidics, robotic liquid-handling technologies, and next-generation sequencing library preparation kits.
PerkinElmer will be able to better partner with academic, pharmaceutical, and biopharmaceutical scientists to provide tools for exploring next-generation cell engineering and customized cell lines for precision medicine.
Horizon is headquartered in Cambridge, U.K. and is a producer of CRISPR and RNA interference reagents, cell models, cell engineering, and base editing technologies. The company has approximately 400 employees in multiple countries and reported revenue of $75.5 million in 2019.